Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). ORBIT-4 is the second of the two Phase III pivotal

FDA OOPD grants orphan drug designation to Alitair’s Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate, Erdosteine®, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties. Alitair President and CEO William Howard said, "We are excited

Adults with Bronchiectasis at Higher Risk of Depression and Anxiety, Study Shows

Like many chronic lung disease patients, those with non cystic bronchiectasis, are also at a higher risk of depression and anxiety, according to recent research. The study, “Factors related to depression and anxiety in adults with bronchiectasis,” is published in the journal Neuropsychiatric Disease and Treatment. As a chronic disease, bronchiectasis affects a person’s ability to exercise and can make daily living

Bronchiectasis Awareness

Bronchiectasis Awareness poster If you could help us raise awareness of Bronchiectasis by downloading the Bronchiectasis Awareness poster and posting in surgeries and clinics. We can get the message out to look for the symptoms of Bronchiectasis. Many of our community are failing to be diagnosed and misdiagnosed with another respiratory condition.

The 100000 Genomes Project

If you have unexplained Bronchiectasis then you may qualify for the Genomes Project to identify what has caused your bronchiectasis.